Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

YKL-40 in patients with end-stage renal disease receiving haemodialysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Head-to-head comparison of cardiac troponin T and troponin I in patients without acute coronary syndrome: a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Determination of natural moisturizing factors in the skin: Raman microspectroscopy versus HPLC

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40.

METHODS: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment.

RESULTS: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL-1(IQR: 193-291 µgL-1) before HD treatment and 198 µgL-1(IQR: 147-258 µgL-1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2-7.3, p < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1-4.5, p = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment.

CONCLUSION: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.

OriginalsprogEngelsk
TidsskriftBiomarkers
Vol/bind23
Udgave nummer4
Sider (fra-til)357-363
Antal sider7
ISSN1354-750X
DOI
StatusUdgivet - 2018

ID: 53412829